ImmunoGen Inc (IMGN)

[skitahoe]

I believe the Motley Fool characterised how the ESMO report was received, in general the trial fell well short of previous data, but much of this may have been because patients were not in the trial for sufficient time to see the full improvement that would be achieved. It's very possible that the percentage won't reach the over 60% initially reported, but it also could be well above the 30% observed to date.

I believe we'll see positive results when top line data from the Phase 3 trial become available, and that will support approval. In the future they'll establish what combination can further benefit patients. I suspect that we'll hear more during the upcoming quarterly report, as well as learning of additional technical presentations coming up between now and the end of the year.

Gary